TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8194141
Drug: Microinfusion set
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microinfusion set for subcutaneous infusion
Study: 2890268
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 25 mg daily
Study: 2890268
Drug: Furosemide (Lasix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (Lasix Retard, LR) 30 mg daily
Study: 29341984
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of RV1 (early administration)
Study: 29341984
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of RV1 (on-time administration)
Study: 29341984
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of RV1 (late administration)
Study: 29341984
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of RV1 (early administration)
Study: 29341984
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of RV1 (on-time administration)
Study: 29341984
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of RV1 (late administration)
Study: 22943627
Drug: Wellbeing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellbeing therapy (WBT) based on personalized mobile technology
Study: 16284462
Drug: lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine (3TC) - stavudine (d4T) - IDV (800 mg three times daily)
Study: 16284462
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) - d4T - IDV (1000 mg three times daily)
Study: 10513804
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg twice a day) for 12 months
Study: 9816009
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Control group)
Study: 387329
Drug: Imipramine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (75 mg at bedtime)
Study: 21330034
Drug: Comprehensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive and intensive treatment of cardiovascular risk factors
Study: 19084453
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent split virus influenza vaccine
Study: 16968577
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of travoprost 0.004%/timolol 0.5% (T/T)
Study: 16968577
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of latanoprost 0.005%/timolol 0.5% (L/T)
Study: 15519437
Drug: Webster-Stratton parenting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Webster-Stratton parenting program (16-hour weekly intervention)
Study: 11049793
Drug: Paromomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (500 mg 4 times daily for 21 days)
Study: 11049793
Drug: Paromomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paromomycin (500 mg q.i.d. for an additional 21 days)
Study: 7933789
Drug: Acebutolol, 400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol, 400-800 mg/day for 12 weeks
Study: 7933789
Drug: Propranolol, 80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80-160 mg/day for 12 weeks
Study: 3739795
Drug: Multicomponent smoking
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent smoking relapse prevention treatment
Study: 30448901
Drug: Gel with
Normalized name: GEL WITH PUMP (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel with 20% type III/80% type I collagen
Study: 22645201
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 6 months
Study: 16458133
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 325 mg/day
Study: 15100915
Drug: Out-patient rehabilitation
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient rehabilitation (but received in-patient treatment)
Study: 7507201
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose aprotinin
Study: 2879872
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg norfloxacin
Study: 2879872
Drug: TMP-SMZ (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMZ (160 mg/800 mg)
Study: 27283946
Drug: SYN-004 (75-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN-004 (75-750 mg single dose)
Study: 27283946
Drug: SYN-004 (75-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN-004 (75-300 mg multiple doses every 6 hours for 7 days)
Study: 20023707
Drug: Early immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early immunization (3 months) with 7-valent pneumococcal vaccine
Study: 20023707
Drug: Late immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late immunization (9 months) with 7-valent pneumococcal vaccine
Study: 20023707
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of anti-pneumococcal antibodies functionality through opsonophagocytic assay
Study: 12923723
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and cytotoxic agents (alternating schedule for 6 months)
Study: 12923723
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and cytotoxic agents
Study: 8299437
Drug: Jet-injected insulin
Normalized name: insulin degludec Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet-injected insulin
Study: 8299437
Drug: Needle-injected insulin
Normalized name: insulin degludec Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-injected insulin
Study: 16400382
Drug: Adjuvant external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant external beam radiotherapy (RTx) in addition to standard therapy
Study: 16400382
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (thyroidectomy, ablative radioiodine therapy, and diagnostic 131I whole-body scintigraphy)
Study: 16489696
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy (74.4-79.2 Gy in 6.2-7 weeks, 1.2 Gy per fraction twice a day)
Study: 16489696
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Conventional, Hyperfractionated, Accelerated)
Study: 16531613
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12
Study: 16554525
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg
Study: 16554525
Drug: Sertraline (238
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (238 patients) at a maximal daily dose of 200 mg
Study: 16554525
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg
Study: 16554526
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion (up to 400 mg per day)
Study: 16554526
Drug: Buspirone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (up to 60 mg per day)
Study: 16554527
Drug: ACAT inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAT inhibitor pactimibe (100 mg per day)
Study: 16563165
Drug: Weekly pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pediatric evaluation and referral to appropriate care for infants with cleft lip and/or palate.
Study: 16628299
Drug: Parenteral penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral penicillin or oral amoxicillin (WHO standard treatment)
Study: 16681848
Drug: Cetuximab (Erbitux)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (Erbitux) plus intensity-modulated radiation therapy (IMRT)
Study: 16714187
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole (30-325 mg daily + 200 mg twice daily)
Study: 16714187
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (30-325 mg daily)
Study: 16757724
Drug: Sunitinib, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.
Study: 16764734
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no intervention towards prescription patterns in elderly, but educational intervention for antibiotics.
Study: 16775234
Drug: Dasatinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (15 to 240 mg per day) administered orally in four-week treatment cycles, once or twice daily.
Study: 16775235
Drug: Nilotinib (AMN107)
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib (AMN107) at various doses (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg once daily; 400 mg and 600 mg twice daily)
Study: 16781217
Drug: Fludrocortisone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.05 to 0.2 mg
Study: 16831964
Drug: Mitoxantrone hydrochloride,
Normalized name: MitoXANTRONE Hydrochloride, 2 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone hydrochloride, 12 mg/m2, administered monthly via intravenous infusion for 6 months followed by 3 additional treatments every 3 months
Study: 16864730
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion after endotoxin administration
Study: 16864730
Drug: K-channel blocker
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-channel blocker tetraethylammonium (TEA)
Study: 16864730
Drug: NO synthase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA)
Study: 16875985
Drug: Ranolazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (1000 mg twice a day for 6 weeks)
Study: 16880310
Drug: Traditional diagnostic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional diagnostic hysteroscopy with 10 mL of 3% mepivacaine hydrochloride
Study: 16882711
Drug: 5-aza-2'-deoxycytidine (decitabine)
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aza-2'-deoxycytidine (decitabine) 15 mg/m² IV daily for 10 days + valproic acid (VPA) escalating doses orally for 10 days (maximum 50 mg/kg daily)
Study: 16899778
Drug: Anakinra (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (1 to 2 mg per kilogram of body weight per day subcutaneously)
Study: 16901335
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (INH, Exubera)
Study: 16901335
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) insulin and other licensed therapies
Study: 16925569
Drug: Single-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose rituximab
Study: 16952304
Drug: Anti-CCR4 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CCR4 monoclonal antibody (mAb)
Study: 16959033
Drug: Candesartan (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (up to 32 mg/day during 6 months)
Study: 17012043
Drug: Risk-adapted craniospinal
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted craniospinal radiotherapy followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy
Study: 17018123
Drug: Steroid-free immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppressive regimens
Study: 17018123
Drug: Monotherapy for
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy for immunosuppression (12 on sirolimus)
Study: 17018123
Drug: Campath-1H and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath-1H and sirolimus therapy
Study: 17021321
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg for 21 days every 4 weeks or daily)
Study: 17079762
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment (scaling and root planing before 21 weeks of gestation) with monthly tooth polishing and oral hygiene instruction
Study: 17090650
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal conjugate vaccine (7vPCV), administered in 3 consecutive doses in monthly intervals starting 6 to 9 months after alloHSCT
Study: 17109179
Drug: Wide excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide excision as initial therapy
Study: 17109179
Drug: Wide excision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide excision as salvage therapy
Study: 17109179
Drug: No neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neoadjuvant or adjuvant therapy
Study: 17116834
Drug: Imiquimod treatment
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod treatment (self-applied cream or suppositories, 3 times a week for 16 weeks)
Study: 17130304
Drug: N(G)-Monomethyl-l-arginine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) during autonomic blockade
Study: 17130304
Drug: N(G)-Monomethyl-l-arginine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-Monomethyl-l-arginine (250 microg/kg per minute IV) in intact subjects
Study: 17133154
Drug: Levofloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (10 mg/kg twice a day for 10 days)
Study: 17174643
Drug: Other evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other evidence-based beta blockers
Study: 17183730
Drug: Hydralazine (182
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (182 mg for rapid-acetylators, 83 mg for slow-acetylators) and magnesium valproate (30 mg/kg) added to neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every 21 days.
Study: 17242628
Drug: Atomoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (up to 1.8 mg/kg/day)
Study: 17263626
Drug: Interferon/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon/ribavirin therapy
Study: 17337677
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline inhalation
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine < 0.9 mg/dl
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine 0.9-1.2 mg/dl
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine 1.2-1.6 mg/dl
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine 1.6-2.8 mg/dl
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine >= 2.8 mg/dl
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine (per mg/dl) in LIFE study
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine (per mg/dl) in RENAAL study
Study: 17351381
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum creatinine (per mg/dl) in combined studies
Study: 17356709
Drug: 5,6-dimethylxanthenone-4-acetic acid
Normalized name: 5,6-Dimethylxanthenone-4-acetic acid
DrugBank: Vadimezan (DB06235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,6-dimethylxanthenone-4-acetic acid (DMXAA) 30 mg/kg, i.p.
Study: 17362525
Drug: Soluble triggering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble triggering receptor expressed on myeloid cells (sTREM)-1
Study: 17379851
Drug: Five deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five deep inspirations before methacholine inhalation
Study: 17395103
Drug: Inactive antibody
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive antibody
Study: 17425446
Drug: Pramlintide therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide therapy (120 microg)
Study: 17426205
Drug: (18)F-FMT PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: (18)F-FMT PET in combination with (18)F-FDG PET
Study: 17426276
Drug: High-dose immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST)
Study: 17426276
Drug: High-dose immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppression followed by AHST
Study: 17436219
Drug: Lopinavir/ritonavir (highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (highly active antiretroviral therapy)
Study: 17450048
Drug: Adjunct services
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct services for attrition prevention (ASAP)
Study: 17498579
Drug: BNP quartile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP quartile Q1 (<430 pg/ml)
Study: 17498579
Drug: BNP quartile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP quartile Q2 (430 to 839 pg/ml)
Study: 17498579
Drug: BNP quartile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP quartile Q3 (840 to 1,729 pg/ml)
Study: 17498579
Drug: BNP quartile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP quartile Q4 (>=1,730 pg/ml)
Study: 17502467
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (10 g daily, containing 100 mg of testosterone)
Study: 17503986
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day for 6 weeks, increased to 120 mg/day for the remainder of the 12-week trial as tolerated
Study: 17504901
Drug: Ghrelin measurement
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin measurement (hourly between 2300 and 0300 h)
Study: 17507719
Drug: Vascular targeted
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular targeted photodynamic therapy (VTP) with palladium-bacteriopheophorbide
Study: 17515522
Drug: Oral bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral bexarotene and extracorporeal photopheresis
Study: 17519207
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet gel (APG)
Study: 17519207
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (antibiotic ointment and/or semiocclusive dressing)
Study: 17519207
Drug: Topical autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical autologous platelet gel (APG) with platelet count > 6 times baseline
Study: 17536019
Drug: Sildenafil (a
Normalized name: sildenafil (as citrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (a phosphodiesterase-5 inhibitor)
Study: 17541048
Drug: Augmentation pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation pharmacotherapy (bupropion, nortriptyline, or lithium)
Study: 17541048
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation (control group)